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ABSTRACT 
A history of the development of live attenuated varicella vac- 
cine and its current use is presented. The vaccine is highly pro- 
tective against severe varicella in all populations that have been 
studied. Vaccination of a healthy varicella-susceptible popula- 
tion is safe. Rarely the vaccine virus may be transmitted to vari- 
cella-susceptible contacts, resulting in an attenuated illness. 
Clinical reversion of vaccine virus to virulence has not been 
observed. Immunologically, adults do not respond as robustly 
as children to the vaccine; therefore two doses are recom- 
mended for individuals over 13 years of age, given 1 to 2 
months apart. The epidemiology of zoster, which currently 
affects about 15% of the population, may also change with 
widespread vaccine use. In leukemic children, the incidence of 
zoster is reduced following immunization. It is predicted that 
zoster may also be less prevalent in healthy vaccinated persons; 
however, it will take a number of years before this can be 
demonstrated. Live attenuated varicella vaccine is now licensed 
for routine use to prevent varicella in many countries in Asia, 
in the United States, and in certain European countries. 
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The Oka strain of live attenuated varicella vaccine was 
developed in the early 1970s in Japan, by Takahashi and 
his colleagues.’ The vaccine was licensed in Japan and 
Korea in 1987, and by the Food and Drug Administration 
(FDA) in the United States, for routine use for varicella- 
susceptible children and adults, in March 1995. 
Varicella vaccine is unique. Varicella-zoster virus 
(VZV) is a member of the herpesvirus group. These 
viruses characteristically cause latent infection follow- 
ing primary infection. Live attenuated varicella vaccine 
is the first live herpesvirus vaccine to be widely used to 
protect the susceptible population from chickenpox, 
although it is appreciated that the vaccine virus causes 
latent infection.2,3 
Varicella vaccine is the first live vaccine to be admin- 
istered extensively to immunocompromised patients. Vac- 
cine studies in the United States were initiated in a high 
risk immunocompromised group, children with under- 
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lying leukemia receiving maintenance chemotherapy who 
were at high risk to manifest severe and even fatal nat- 
ural varicella.*a5 Varicella vaccine may be useful as a ther- 
apeutic vaccine to abort reactivation of latent infection. 
Since boosting of immunity occurs following re-exposure 
of an immune individual to VW6 there is considerable 
interest in determinin g whether live varicella vaccine can 
be used not only to prevent chickenpox but also to pre- 
vent zoster, by interfering with reactivation of latent VZV 
In practice, varicella vaccine is a more complicated 
vaccine than other available live vaccines against viral 
infections. Although the likelihood of developing full- 
blown varicella is extremely low after vaccination, the 
possibility of developing a minor rash due to VZV in the 
weeks to years after immunization may be as high as 15% 
in healthy children and 30% in healthy adults. Approxi- 
mately 5% of immunized children may develop a vaccine- 
associated rash about a month after immunization, 10% 
may experience mild breakthrough varicella, and less 
than 1% would be predicted to develop zoster. Approx- 
imately 10% of immunized adults may develop a vaccine- 
associated rash about a month after immunization, 20% 
may experience mild breakthrough varicella, and again, 
less than 1% are predicted to develop zoster. In instances 
where a rash is unusual and suspected to be attributable 
to VZV; use of various diagnostic methods to identify the 
cause of these rashes and whether they are attributable 
to vaccine or wild-type VZV is indicated.7-9 
OKa STRAIN OF VARICELLA-ZOSTER VIRUS 
All of the currently available live varicella vaccines are 
derived from the parent Oka strain, and differ only in pas- 
sage of the virus used and in stabilizers and other com- 
ponents of the vehicle. These products are manufactured 
by Merck (West Point, PA) in the United States, by 
SmithKline Beecham (Rixensart, Belgium) in Europe, 
and by the Biken Institute in Japan. The Oka strain was 
isolated from a 3-year-old Japanese boy during an attack 
of varicella in 1972. The isolate was passaged 11 times 
in human embryonic lung fibroblasts at 34°C 12 times 
in guinea pig fibroblast cells at 37°C and 7 to 8 times 
in MRC-5 cells at 37°C. A sonicate of the resultant pas- 
saged virus, containing 1500 to 5000 plaque-forming 
units (pfu) was administered to 71 hospitalized children 
to try to abort a potential outbreak of varicella. The vac- 
cine was immunogenic and exhibited short-term safety 
in these children, none of whom developed any symp- 
toms of varicella.’ 
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Table 1. Overview of Estimated Adverse Effects, Seroconversion Rates, Efficacy, and Occurrence of Zoster in Various Populations 
Immunized1 with Live Attenuated Varicella Vaccine 
Vaccine-Associated Rash (%) Seroconversion (%) 
Dose I Dose 2 Dose 1 Dose 2 EstimatedEfficacy (%) Zoster 
Children 5 - 
Adolescents and adults 5-10 1 
Leukemic children 50 IO 
*Expected rate for this age group 20-59/i O0,00039; +Caused by wild-type VZV 
97 - 
75 99 
82 95 
90 18/l 00,000 
70 1 case+ 
90 2-3% 
Subsequently, hundreds of children with a variety of 
underlying medical problems, including some .who were 
immunocompromised and receiving steroids, were immu- 
nized in numerous studies in Japan.10-12 
Indications that the Oka Strain of Varicella-Zoster 
Virus Is Attenuated 
Since there is no practical animal model for VZTJ in which 
attenuation might be determined, all the available evi- 
dence for attenuation is derived from studies involving 
humans. Attenuation of the vaccine virus seems highly 
likely, since immunization by the subcutaneous route 
causes skin lesions in only 5 to 10% of healthy recipients 
of the vaccine, and it rarely induces a varicella-like syn- 
drome. In addition, vaccination by inhalation of 800 pfu 
of vaccine-type VZV did not induce disease in eight sus- 
ceptible children. l3 
Transmission of vaccine-type VZV from leukemic vac- 
cine recipients with a vaccine-associated rash to varicella- 
susceptible siblings has been observed, but at a rate of 
only 14%.l”,14 In contrast, the transmission rate of wild- 
type varicella to susceptible individuals aftelr a similar 
type of exposure is SO to 9O%.‘j Most importantly, in con- 
tact cases in healthy children caused by the Oka strain, 
the reported subclinical attack rate was 27%, in contrast 
to the predicted 5% in wild-type infection. Thle reported 
average number of skin lesions was 38 in contact cases, 
about 10 times less than would be predicted to occur 
with wild-type infection.i4Although there are demon- 
strable differences in the DNA of the Oka strain and wild- 
type VZV circulating in North America, the molecular 
basis for the attenuation of VZV is not known. 
Differentiation of the Oka Strain of Varicella-Zoster 
Virus from Wild--e Varicella-Zoster Virus 
It has been possible to differentiate between vaccine- 
type and wild-type WV since the early 19SOs, using 
restriction enzymes and analysis of the resulting DNA 
fragments, although prior isolation of WV in cell culture 
is required.4l16 Subsequently polymerase chain reaction 
(PCR) was combined with restriction enzyme technol- 
ogy for this distinction, a significant advance, because 
successful virus isolation is not a prerequisitle.9 For the 
PCR assay, two primer pairs are used, one that generates 
a 222 base-pair (bp) fragment asymmetrically flanking a 
novel Bgl-I restriction site in vaccine-type VZV and 
another that generates a 350 bp fragment asymmetrically 
flanking a Pst-I site that is preserved in all wild-type VZVs 
but not in the Oka strain.9 The amplification products 
are subjected to digestion with Bgl-I and Pst-I restriction 
enzymes, and the fragments are separated by elec- 
trophoresis. By examining the number and sizes of the 
DNA fragments, it is possible to distinguish between wild- 
type VZV and Oka VZS? The restriction fragment length 
polymorphisms @FLP) are not due to attenuation but to 
differences between circulating VZVs in the United States 
and those in Japan, where the Oka strain originated.9 The 
PCR assay is therefore not as useful in Japan as it is in 
North America. 
CLINICAL TRIALS IN NORTH AMERICA 
Clinical trials, conducted roughly from 1980 to 1994, 
involved almost 600 children with leukemia, approxi- 
mately 9000 healthy children, and about 2000 healthy 
adolescents and adults, all of whom were susceptible to 
varicella when they were vaccinated. These trials led to 
the approval of live attenuated varicella by the FDA, in 
March 1995, for healthy children and adults who are sus- 
ceptible to varicella. In the American clinical trials, open 
label clinical trials were initiated in children with 
leukemia in remission for at least 1 year. These children 
were recognized to be at high risk to develop severe vari- 
cella, because it had been reported that 30% of leukemic 
children receiving steroids developed disseminated chick- 
enpox, and 7% died from varicel1a.l’ In clinical trials, 
leukemic children lacking a history of chickenpox and 
with undetectable levels of antibody to VZV were vacci- 
nated and followed longitudinally for the safety, immuno- 
genic&y, and protective efficacy of the vaccine.4,18 The 
vaccine proved to be safe and resulted in complete pro- 
tection from severe varicella, although some children 
experienced modified breakthrough cases of varicella. 
Theoretically one might have expected that over a lo- 
year period, there might have been 75 to 100 cases of dis- 
seminated varicella, with possibly 25 deaths from this 
infection if the children had not been immunized. 
Instead there were no deaths attributed to VZV in vac- 
cinated children. In these vaccine recipients, the attack 
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rate of varicella after household exposure was 17 of 123 
(14%) instead of the 80 to 90% attack rate predicted for 
varicella-susceptible individuals. Moreover, the break- 
through cases of varicella were modified with an average 
of about 100 skin lesions, at the very least, 5 times fewer 
lesions than would normally be predicted for a leukemic 
child. ‘* In the short-term, varicella vaccine induced few 
adverse effects in the month after immunization. The 
adverse event that gave the greatest degree of concern 
was development of a vaccine-associated rash that 
required therapy with an antiviral drug in roughly 20% of 
leukemic recipients of the vaccine.ls Not only was immu- 
nization found to protect leukemic children from vari- 
cella, it was demonstrated to protect against zoster as 
well. Vaccine-type VZV can establish latent infection, and 
it can cause zoster in leukemic recipients.2s9 The inci- 
dence of roster following vaccination, however, is sig- 
nificantly lower than following natural infection. In a 
study of 96 vaccine recipients and 96 controls who had 
leukemia and natural varicella, followed longitudinally 
for several years after immunization, the rate of zoster 
was 2% in vaccine recipients and 15% in controls.19 After 
a follow-up of 11 to 13 years, 87% of leukemic children 
remained VZV seropositive. Neither the incidence or the 
severity of breakthrough varicella in leukemic children 
has increased over time in follow-up studies lasting up to 
13 years.18 
CLINICAL TRIALS IN HEALTHY ADULTS AND 
ADOLESCENTS 
Adults who develop varicella are at risk to develop severe 
infection. Therefore, immunization of varicella-suscepti- 
ble healthy adults was carried out in early clinical trials; 
these involved 288 adults in the Collaborative Varicella 
Vaccine Study. 18,20 Adults were found to have twice the 
chance of developing a vaccine-associated rash as healthy 
children, and although no vaccinated adult developed a 
severe vaccine-associated rash, on occasion it was possi- 
ble to isolate vaccine-type VZV from transient skin 
lesions.‘O Adults required two doses of vaccine to achieve 
a seroconversion rate greater than 90%.20 These obser- 
vations are probably related to the fact that adults have 
lower cell-mediated immune responses than healthy chil- 
dren after varicella immunization.1s~20~21 
Whether the vaccine was protective was usually 
determined by comparing the attack rate of varicella fol- 
lowing household exposure to chickenpox in vaccine 
recipients with the known attack rate of 80 to 90% in sus- 
ceptible individuals after intimate exposure.15 Forty-three 
of 58 (74%) healthy adults did not develop varicella after 
household exposure to varicella. Those with break- 
through disease had a modified illness with a mean of 
43 skin lesions. After up to 13 years of follow-up, 82% of 
adults remained seropositive. Neither the incidence nor 
the severity of breakthrough varicella in adults increased 
with time.” Only one vaccinated adult developed clini- 
cal zoster; this was caused by wild-type VZV22 
CLINICAL TRIALS IN HEALTHY CHILDREN IN 
THE UNITED STATES 
Only minor adverse effects have been reported in 
healthy child recipients of vaccine: 19% had pain at the 
injection site, and 6% had a rash at the injection site or 
a mild varicella-like rash.23 Most of the children with a 
vaccine-associated rash had fewer than 10 lesions, most 
of which were not vesicular. Children under 12 years of 
age had a 97% seroconversion rate.24 Adolescents (over 
age 13) had an 82% seroconversion rate after one dose 
and a 99% seroconversion rate after two doses.25 Anti- 
body titers remained positive in over 95% for up to 4 to 
6 years in over 200 reported American children.26-28 
Breakthrough cases of varicella occurred in approxi- 
mately 1 to 2% of a cohort during each year of a -/-year 
follow-up, but represented a modified form of chicken- 
pox. 25,28 Studies performed in healthy children indicate 
that varicella occurring after immunization is a modified 
illness in healthy children.29 In 114 children with break- 
through varicella 6 to 8 years after immunization, only 
39% had itching, 9% had fever, 7% had lymphadenopa- 
thy, and 2% had malaise in addition to a skin rash with, 
on average, about 20 skin lesions. The median time lost 
from school was 2 days, in contrast to a reported 8 days 
after natural varicella.29 A cost-benefit analysis for vaccine 
use in the United States indicated that routine use of 
varicella vaccine would save $5 for every $1 spent, if 
benefits to society and to the individual are taken into 
account.30 
One double-blind controlled study of the efficacy of 
varicella vaccine in healthy children in the United States 
has been performed in which 491 children were vacci- 
nated and 465 received placebo.31 During the first year 
after receipt of vaccine or placebo the incidence of vari- 
cella was 0 and 8.5%, respectively, a vaccine efficacy of 
100%. In the second year of follow-up, involving less 
than half of these subjects, the efficacy was 96%. The 
17,430 pfu vaccine used for this study may account for 
the extremely high efficacy rate.23 The currently licensed 
vaccine contains 2900 to 9000 pfu. 
The overall efficacy of varicella vaccine in healthy 
children in the currently licensed products is greater 
than 90%, based on a 9% annual incidence of natural 
varicella in healthy school children. The immunizing 
dose of virus plays a critical role in vaccine efficacy. In 
clinical trials performed with vaccine available in 1987, 
involving 4142 children given 1000 to 1625 pfu, the 
annual attack rate of breakthrough varicella was 2.1 to 
3.6%, a reduction of disease over 6 years of 67%. In later 
trials with vaccine prepared in 1991, in 1164 children 
given 2900 to 9000 pfu, the annual attack rate of break- 
through varicella was 0.2 to l%, a reduction of disease 
over 3 years of 93%.23 
RECOMMENDATIONS FOR USE OF VARICELLA 
VACCINE IN THE UNITED STATES 
Based on the clinical trials described above, the FDA and 
the American Academy of Pediatrics have madle the fol- 
lowing recommendations for use of live attenttated vari- 
cella vaccine in the United States.23,32 
Healthy children who are more than 12 months of age 
and who have not had varicella should be immunized 
with one dose of vaccine. 
Two doses of vaccine given 1 to 2 months apart are 
recommended for adolescents who have reached their 
13th birthday and for adults. 
The vaccine should not be administered to immuno- 
compromised children (other than those with leukemia 
in remission for at least 1 year, under a special FDA 
approved program), pregnant women, or children with 
serious intercurrent conditions. 
LONG-TERM CONCERNS REGARDING VARICELLA 
VACCINE 
The major long-term concern continues to be the dura- 
bility of protective immunity to varicella after immu- 
nization. Traditionally the duration of immunity after 
vaccination is assessed by determining the rate of the 
persistence of detectable antibodies. As discussed, con- 
cerning individual groups, antibody persistence has been 
best in healthy children (>95%). In the United States, 
antibody persistence has been examined for as long as 6 
years following immunization. A 20-year follow-up study 
of people vaccinated in Japan revealed that positive VZV 
antibody titers were detectable in 25 of 25 individuals 
tested, with similar persistence of cell-mediated immunity 
to VZV, as determined by skin testing.33 There was a clin- 
ical follow-up of 96 vaccine recipients for this period that 
indicated an overall rate of breakthrough varicella of 2%. 
Thus, in healthy individuals immunized during childhood, 
the persistence of immunity to VZV appears to be excel- 
lent for the period during which it has been possible to 
examine it. 
Whether boosting of the immune system due to 
exposure of immune individuals to VZV plays a role in 
maintenance of immunity needs to be investigated. Cur- 
rently, boosting after re-exposure to VZV is recognized to 
be common, but the importance of re-exposure in long- 
term maintenance of immunity to VZV is unknown. In 
the United States, the FDA has mandated that studies on 
approximately 50,000 immunized children will be 
conducted over a period of at least 15 years to deter- 
mine the breakthrough rate of varicella.23 This approach 
should provide important answers to these questions and 
determine whether booster immunizations against vari- 
cella will need to be recommended. 
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There is concern about the possible transmission of 
vaccine virus from vaccine recipients to varicella sus- 
ceptible individuals between whom there is close con- 
tact, and of wild-type VZV from vaccine recipients with 
breakthrough infections. Both have been observed~5~10,‘4~34 
but the frequency with which such transmission occurs 
is not known, especially from healthy vaccine recipients. 
Based on experience during the first year of licensure of 
varicella vaccine in the United States, spread of vaccine- 
type VZV to others from healthy vaccinated children 
appears to be an extremely rare event. 
FUTURE DIRECTIONS 
Responses in children who require organ transplantation 
and those with chronic diseases with regard to safety and 
immunogenicity of varicella vaccine need to be assessed. 
Vaccine studies would be appropriate in children with 
asthma or cancer (especially those receiving steroids), dia- 
betes, human immunodeficiency virus (HIV) infection, or 
rheumatoid arthritis for which aspirin therapy is given. 
Zoster now occurs in approximately 15% of the popula- 
tion of varicella-immune individuals over a lifetime. Usu- 
ally zoster develops when the cell-mediated immune 
response to VZV decreases with advancing age or inter- 
current disease.1xa35 To date, all indications in healthy vac- 
cinated populations are that the incidence of zoster is 
lower following vaccination than after natural infection.18 
It is hoped that this will hold true as individuals who were 
immunized as children enter middle age, when they are 
at risk to develop zoster due to declining cellular immu- 
nity to VZV; but it will be many years before this can be 
determined. Since additional doses of vaccine can increase 
cell-mediated immunity to VZV36-38 it may be that vari- 
cella-immune individuals at high risk to develop zoster 
can be protected by administration of varicella vaccine. 
It has been observed that leukemic children who 
received two doses of varicella vaccine are less likely to 
develop roster than those who were given only one 
dose.6 In a study involving 202 individuals with a past 
history of varicella, aged 55 to 87 years, an increase in 
cell-mediated immune responses occurred in 85 to 90% 
that lasted for as long as 4 years after administration of 
one dose of live varicella vaccine.38 There were eight pos- 
sible cases of zoster in those immunized, but all cases 
were exceptionally mild with an average of only 4 days 
of pain and only minor rashes. A planned double-blind 
placebo-controlled study in elderly individuals will make 
it possible to determine more clearly the efficacy of vari- 
cella vaccine to prevent or modify zoster. 
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